A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease.

MLA

Kim, Gi-Ae, et al. “A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease.” Pharmaceuticals (Basel, Switzerland), vol. 16, no. 4, Apr. 2023. EBSCOhost, https://doi.org/10.3390/ph16040623.

APA

Kim, G.-A., Cho, H. C., Jeong, S. W., Kang, B.-K., Kim, M., Jung, S., Hwang, J., Yoon, E. L., & Jun, D. W. (2023). A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease. Pharmaceuticals (Basel, Switzerland), 16(4). https://doi.org/10.3390/ph16040623

Chicago

Kim, Gi-Ae, Hyun Chin Cho, Soung Won Jeong, Bo-Kyeong Kang, Mimi Kim, Seungwon Jung, Jungwook Hwang, Eileen L Yoon, and Dae Won Jun. 2023. “A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease.” Pharmaceuticals (Basel, Switzerland) 16 (4). doi:10.3390/ph16040623.